北京
分享至
瑞博生物-B(06938.HK)公布，已在欧盟提交公司靶向INHBE 的siRNA产品RBD3133注射液以超重及肥胖症为治疗适应症的I期临床试验申请。
本文源自：金融界AI电报
特别声明：以上内容(如有图片或视频亦包括在内)为自媒体平台“网易号”用户上传并发布，本平台仅提供信息存储服务。
Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.
